• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尾加压素II在心血管疾病中的新作用。

Emerging roles of urotensin-II in cardiovascular disease.

作者信息

Russell Fraser D

机构信息

Vascular Biology Laboratory, Department of Medicine, The University of Queensland, Brisbane, The Prince Charles Hospital, Pathology Building, Rode Road, Ground Floor, Room 3, Chermside 4032, Queensland, Australia.

出版信息

Pharmacol Ther. 2004 Sep;103(3):223-43. doi: 10.1016/j.pharmthera.2004.07.004.

DOI:10.1016/j.pharmthera.2004.07.004
PMID:15464591
Abstract

Urotensin-II (UII) is a highly potent endogenous peptide within the cardiovascular system. Through stimulation of Galphaq-coupled UT receptors, UII mediates contraction of vascular smooth muscle and endothelial-dependent vasorelaxation, and positive inotropy in human right atrium and ventricle. A pathogenic role of the UT receptor system is emerging in cardiovascular disease states, with evidence for up-regulation of the UT receptor system in patients with congestive heart failure (CHF), pulmonary hypertension, cirrhosis and portal hypertension, and chronic renal failure. In vitro and in vivo studies show that under pathophysiological conditions, UII might contribute to cardiomyocyte hypertrophy, extracellular matrix production, enhanced vasoconstriction, vascular smooth muscle cell hyperplasia, and endothelial cell hyper-permeability. Single nucleotide polymorphisms of the UII gene may also impart a genetic predisposition of patients to diabetes. Therefore, the UT receptor system is a potential therapeutic target in the treatment of cardiac, pulmonary, and renal diseases. UT receptor antagonists are currently being developed to prevent and/or reverse the effects of over-activated UT receptors by the endogenous ligand. This review describes UII peptide and converting enzymes, and UT receptors in the cardiovascular system, focusing on pathophysiological roles of UII in the heart and blood vessels.

摘要

尾加压素II(UII)是心血管系统中一种高效的内源性肽。通过刺激与Gαq偶联的UT受体,UII介导血管平滑肌收缩、内皮依赖性血管舒张,以及人右心房和心室的正性肌力作用。UT受体系统在心血管疾病状态中正在显现出致病作用,有证据表明充血性心力衰竭(CHF)、肺动脉高压、肝硬化和门静脉高压以及慢性肾衰竭患者的UT受体系统上调。体外和体内研究表明,在病理生理条件下,UII可能导致心肌细胞肥大、细胞外基质产生、血管收缩增强、血管平滑肌细胞增生以及内皮细胞高通透性。UII基因的单核苷酸多态性也可能使患者具有患糖尿病的遗传易感性。因此,UT受体系统是治疗心脏、肺部和肾脏疾病的潜在治疗靶点。目前正在研发UT受体拮抗剂,以预防和/或逆转内源性配体过度激活UT受体的作用。这篇综述描述了心血管系统中的UII肽和转换酶以及UT受体,重点关注UII在心脏和血管中的病理生理作用。

相似文献

1
Emerging roles of urotensin-II in cardiovascular disease.尾加压素II在心血管疾病中的新作用。
Pharmacol Ther. 2004 Sep;103(3):223-43. doi: 10.1016/j.pharmthera.2004.07.004.
2
Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.高血压大鼠心血管器官中尾加压素II、尾加压素II相关肽及尾加压素II受体mRNA表达增加:与内皮素-1的比较
Peptides. 2009 Jun;30(6):1124-9. doi: 10.1016/j.peptides.2009.02.009. Epub 2009 Feb 21.
3
Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.
Curr Opin Investig Drugs. 2004 Mar;5(3):276-82.
4
Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure.充血性心力衰竭大鼠心脏中尾加压素II相关肽的基因表达增加。
Peptides. 2008 May;29(5):801-8. doi: 10.1016/j.peptides.2007.12.018. Epub 2008 Jan 20.
5
Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor.尾加压素II在外周组织中作为自分泌/旁分泌生长因子的作用。
Peptides. 2004 Oct;25(10):1775-81. doi: 10.1016/j.peptides.2004.03.028.
6
Urotensin II: lessons from comparative studies for general endocrinology.尾加压素II:普通内分泌学比较研究的经验教训
Gen Comp Endocrinol. 2008 May 15;157(1):14-20. doi: 10.1016/j.ygcen.2008.03.010. Epub 2008 Mar 16.
7
Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy.糖尿病心肌病中尾加压素II及其受体的表达升高。
J Diabetes Complications. 2008 Mar-Apr;22(2):137-43. doi: 10.1016/j.jdiacomp.2006.10.008.
8
Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction.小鼠中尾加压素 II 的特性、尾加压素 II、尾加压素 II 相关肽及 UT 受体 mRNA 的分布:尾加压素 II 存在于神经肌肉接头处的证据
J Neurochem. 2008 Oct;107(2):361-74. doi: 10.1111/j.1471-4159.2008.05624.x. Epub 2008 Aug 14.
9
Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro.尾加压素 II 及其受体(UT-R)在大鼠脑内皮细胞中表达,且尾加压素 II 通过 UT-R 在体内和体外刺激血管生成。
Int J Mol Med. 2006 Dec;18(6):1107-12.
10
Urotensin II, a novel peptide in central and peripheral cardiovascular control.尾加压素II,一种在中枢和外周心血管调控中的新型肽。
Peptides. 2004 Oct;25(10):1759-66. doi: 10.1016/j.peptides.2004.04.016.

引用本文的文献

1
Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?血管活性肽介导的血脑屏障短暂开放增加脑内药物递送:现实还是一厢情愿?
Curr Neuropharmacol. 2022;20(7):1383-1399. doi: 10.2174/1570159X20999220131163504.
2
Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway.尾加压素II通过CSE/H2S途径保护心肌细胞免受氧化应激诱导的凋亡。
Int J Mol Sci. 2015 Jun 3;16(6):12482-98. doi: 10.3390/ijms160612482.
3
A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.
勃起功能障碍的一种新治疗方法:尾加压素 II 受体高亲和力激动剂配体
Asian J Androl. 2015 Jan-Feb;17(1):81-5. doi: 10.4103/1008-682X.133322.
4
Association between human urotensin II and essential hypertension--a 1:1 matched case-control study.人尾加压素II与原发性高血压的关联——一项1:1匹配病例对照研究。
PLoS One. 2013 Dec 10;8(12):e81764. doi: 10.1371/journal.pone.0081764. eCollection 2013.
5
Endogenous urotensin II selectively modulates erectile function through eNOS.内源性尾加压素 II 通过 eNOS 选择性调节勃起功能。
PLoS One. 2012;7(2):e31019. doi: 10.1371/journal.pone.0031019. Epub 2012 Feb 2.
6
In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.体外 siRNA 介导的 UT 受体敲低:密度对一系列 UT 配体疗效的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2012 Jun;385(6):651-6. doi: 10.1007/s00210-012-0728-0.
7
A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.大鼠脑 uro 素 II 受体表达图谱及中枢 uro 素 II 作用综述
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jul;382(1):1-31. doi: 10.1007/s00210-010-0503-z. Epub 2010 Apr 27.
8
Urotensin II in cardiovascular regulation.心血管调节中的尾加压素II
Vasc Health Risk Manag. 2008;4(4):775-85. doi: 10.2147/vhrm.s1983.
9
Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.尾加压素II可急性增加心肌长度和扩张性:对舒张功能和心室重构的潜在影响。
Naunyn Schmiedebergs Arch Pharmacol. 2007 Oct;376(1-2):107-15. doi: 10.1007/s00210-007-0180-8. Epub 2007 Aug 14.
10
Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.慢性给予尾加压素II对有和没有主动脉-腔静脉瘘的动物的血流动力学影响。
Peptides. 2007 Aug;28(8):1483-9. doi: 10.1016/j.peptides.2007.04.018. Epub 2007 May 6.